phrykt

CytomX Therapeutics, Inc. (CTMX): who owns it and who trades it

As of Nov 16, 2026, CTMX insiders reported 5 open-market sales worth $1.2M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sean A. McCarthy (CEO), with $764K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling CytomX Therapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CTMX

179 funds and institutions reported CTMX shares worth $802M at the end of Q2 2026, about 98% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) 98%Everyone else 2%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
Kynam Capital Management, LP10.0%
BlackRock, Inc.8.1%
Bank of America Corp6.9%
State Street Corp5.4%
Perceptive Advisors LLC4.8%
Vanguard Capital Management LLC3.9%
Point72 Asset Management, L.P.3.6%
Wellington Management Group LLP2.4%
Venrock Adviser, LLC2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)32.71M15.03%$123M+2%
Kynam Capital Management, LP21.70M9.97%$81.4M+45%
BlackRock, Inc.17.56M8.07%$65.8M+236%
Bank of America Corp15.08M6.93%$56.6M+48%
State Street Corp11.75M5.40%$44.1M+107%
Perceptive Advisors LLC10.44M4.80%$39.1M+3%
Vanguard Capital Management LLC8.53M3.92%$32M-2%
Point72 Asset Management, L.P.7.81M3.59%$29.3M-1%
Wellington Management Group LLP5.17M2.37%$19.4M+44%
Venrock Adviser, LLC4.98M2.29%$18.7M-50%
Baker Bros. Advisors LP4.98M2.29%$18.7MNo change
Geode Capital Management, LLC4.68M2.15%$17.5M+126%
Elmind Capital, LP4.55M2.09%$17.1MNo change
Nextech Invest Ltd.4.45M2.04%$16.7MNo change
Two Sigma Investments, LP4.13M1.90%$15.5M+52%
Eversept Partners, LP3.56M1.63%$13.3M+12%
UBS Group AG3.47M1.59%$13M+11%
Siren, L.L.C.3.46M1.59%$13MNo change
ADAR1 Capital Management, LLC3.37M1.55%$12.6M-1%
Citadel Advisors LLC3.11M1.43%$11.7M-42%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CTMX insiders reported $0 of open-market purchases and $1.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.2M
5 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jun 15, 2026
Filed Jun 17, 2026

Purchases and sales by month

$1.2M$1.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 15, 2026Christopher OgdenCFOSale1,624$3.05$5KForm 4
Mar 17, 2026Yu-Waye ChuChief Medical OfficerSale21,279$6.42$137KForm 4
Mar 17, 2026Sean A. McCarthyCEOSale118,969$6.42$764KForm 4
Mar 17, 2026Marcia BelvinVice presidentSale31,492$6.42$202KForm 4
Mar 17, 2026Christopher OgdenCFOSale19,323$6.42$124KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Sean A. McCarthyCEO, Director–$764KMar 17, 2026
Marcia BelvinSVP, Chief Scientific Officer–$202KMar 17, 2026
Yu-Waye ChuChief Medical Officer–$137KMar 17, 2026
Christopher OgdenChief Financial Officer–$129KJun 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CTMX short interest

Very high short interest. 20.8% of CTMX shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 45%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 45.25M CTMX shares were sold short, 20.8% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 3.77M shares, buying them all back would take about 12.0 trading days (days to cover).

Shares short, % of all shares

20.8%May 15Oct 3021.9%

Days to cover

12.0May 15Oct 3017.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202645.25M20.77%+6%3.77M12.0
Oct 15, 202642.79M19.64%+5%3.11M13.8
Sep 30, 202640.81M18.73%+6%4.70M8.7
Sep 15, 202638.64M17.73%+15%4.16M9.3
Aug 31, 202633.51M15.38%-3%2.84M11.8
Aug 14, 202634.62M15.89%-1%2.17M15.9
Jul 31, 202635.11M16.11%-13%2.98M11.8
Jul 15, 202640.32M18.52%+13%3.89M10.4
Jun 30, 202635.57M16.34%+16%8.23M4.3
Jun 15, 202630.61M14.06%+7%3.54M8.7
May 29, 202628.72M13.19%-8%3.09M9.3
May 15, 202631.13M14.30%+5%3.02M10.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

CytomX Therapeutics company events

CytomX Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 27, 2026LeadershipCharles Fuchs, M.D., M.P.H., was appointed to the Board of Directors of CytomX Therapeutics, Inc., effective immediately, as a Class II director, with an initial term expiring at the Company’s 2029 annual meeting of stockholders. Filing
  4. Jun 22, 2026LeadershipStockholders of CytomX Therapeutics, Inc. approved at the Company’s 2026 Annual Meeting of Stockholders an amendment to the Company’s Amended and Restated 2015 Equity Incentive Plan and an amendment to the Company’s Amended and Restated Employee Stock Purchase Plan. Filing
  5. Jun 3, 2026AgreementCytomX Therapeutics, Inc. previously entered into that certain Collaboration and License Agreement, effective November 16, 2022 (as amended, the “Agreement”), with Regeneron Pharmaceuticals, Inc., providing for the collaboration on the creation of conditionally-activated investigational bispecific… Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Mar 19, 2026AnnouncementCytomX Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, in connection with the offering, issuance and sale by the Company of 45,990,567 shares of the Company’s… Filing
  8. Mar 16, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

CytomX Therapeutics financials

Famous investors that hold CTMX

4 of the 50 well-known investors we track reported holding CTMX in their latest 13F filing. The largest position is Steve Cohen's, worth $23.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20268.60M$23.4M0.0%+10%
Ken Griffin · Citadel AdvisorsQ3 20267.01M$19.1M0.0%+125%
Israel Englander · Millennium ManagementQ3 2026263,898$718K0.0%-84%
Paul Tudor Jones · Tudor Investment CorpQ3 2026187,071$509K0.0%-86%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CTMX in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G4.1%
Nov 10, 2026STATE STREET CORPORATION13G4.1%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A5.4%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A5.4%

Questions about CytomX Therapeutics, Inc. (CTMX) stock

Who owns the most CTMX stock?

The largest reported owner of CytomX Therapeutics, Inc. (CTMX) is FMR LLC (Fidelity), with 15.0% of the company. In total, 179 funds and institutions reported holding CTMX at the end of Q2 2026, together about 98% of the shares. See the largest owners.

Are CTMX insiders buying or selling?

In the last 12 months, CTMX insiders reported no open-market purchases and 5 sales worth $1.2M. The latest trade was on Jun 15, 2026. See every trade.

What is the short interest in CTMX?

As of Oct 30, 2026, 45.25M CTMX shares were sold short, 20.8% of the shares outstanding, up 5.7% from the report before. At the average daily volume of 3.77M shares, buying them all back would take about 12.0 trading days (days to cover). See the history.

Which famous investors hold CTMX?

4 of the 50 well-known investors we track reported CTMX in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $23.4M. See all holders.

Executive pay

CytomX Therapeutics's chief executive was paid a total of $4.7M for the year ended Dec 31, 2025, up 170% from $1.8M the year before. In the last 12 months, CytomX Therapeutics's executives and directors bought no stock on the open market and sold $1.7M.

Chief executive, total pay$4.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$10.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.